Accretion Pharmaceuticals IPO
GMP, Subscription, Price, Dates & Financial Details
Accretion Pharmaceuticals Limited, originally established as M/s Accretion Pharmaceuticals, was founded in 2012 by Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra, and Mr. Hardik Mukundbhai Prajapati with the goal of manufacturing healthcare products meeting…
Open Date
Wed, 14 May 2025
Close Date
Fri, 16 May 2025
Price Band
₹ 96 – 101
Lot Size
1200
Issue Size
₹ 29.75 Cr
Minimum Investment
₹ 242,400 (2400 Shares)
Grey Market Premium Analysis
Day Wise GMP→Unofficial premium quoted in the grey market, tracked daily against the price band cap.
Grey market trading is unregulated. GMP figures are indicative only and should not be the sole basis for investment decisions - treat as a sentiment indicator, not a guarantee.
IPO Details
Accretion Pharmaceuticals IPO has successfully completed its IPO process and is now listed on NSE SME Platform. According to the Red Herring Prospectus (RHP), the IPO was a book-built issue with a total issue size of ₹29.75 Crore, comprising a fresh issue of 29.46 Lakh equity shares aggregating to ₹29.75 Crore.
The Accretion Pharmaceuticals IPO remained open for subscription from May 14, 2025, to May 16, 2025. The basis of allotment was finalized on May 19, 2025, and the company's shares were listed on NSE SME Platform on May 21, 2025.
The company had fixed the price band at ₹96 to ₹101 per share, with a lot size of 1200 shares. Retail investors were required to make a minimum investment of ₹242,400 (based on the upper price band) to apply for one lot.
KFin Technologies Limited served as the registrar to the issue. Jawa Capital Services Private Limited acted as the Book Running Lead Managers (BRLMs) to the issue.
With the successful completion of the IPO process, Accretion Pharmaceuticals Limited is now a publicly listed company on NSE SME Platform. Investors can track the company's share price, trading performance, financial results, and corporate announcements through the stock exchanges.
Accretion Pharmaceuticals IPO Timeline (Tentative)
- IPO Open Date
- Wed, 14 May 25
- IPO Close Date
- Fri, 16 May 25
- Basis of Allotment
- Mon, 19 May 25
- Initiation of Refunds
- Tue, 20 May 25
- Credit of Shares to Demat
- Tue, 20 May 25
- Listing Date
- Wed, 21 May 25 — NSE & BSE
Open Date
14 May 2025
Close Date
16 May 2025
Basis Of Allotment
19 May 2025
Listing Date
21 May 2025
IPO Subscription
Check Live Subscription →The Accretion Pharmaceuticals IPO has received bids for 2,00,06,400 shares against 25,87,300 shares offered, resulting in an overall subscription of 7.73x. the NII category is subscribed 4.41x, Retail Investors 10.55x, and QIBs 12.14x.
QIB
12.14x
NII
4.41x
RII
10.55x
Total
7.73x
IPO Reservations
The Retail Individual Investor (RII) category has the highest allocation with 12,22,800 shares, representing 47.26% of the total issue. Qualified Institutional Buyers (QIBs) are allocated 1,41,700 shares (5.48%), while Non-Institutional Investors (NIIs) receive 12,22,800 shares (47.26%).
| Category | Shares Offered | Shares Offered % |
|---|---|---|
| Qualified Institutions | 141,700 | 5.48% |
| Non-Institutional | 1,222,800 | 47.26% |
| Retail Investors | 1,222,800 | 47.26% |
| Total | 2,587,300 | 100% |
Financials Details(₹ in Crores)
| Particular | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 29.34 | 27.05 | 20.58 | 17.74 |
| Revenue | 11.89 | 33.94 | 29.53 | 22.58 |
| Profit After Tax | 1.57 | 3.88 | 0.1 | 0.08 |
| Net Worth | 9.91 | 5.35 | 3.84 | 3.08 |
| Reserve & Surplus | 1.74 | 1.35 | 0 | 0 |
| Total Borrowings | 0 | 0 | 0 | 0 |
Financials Performance
Performance Indicators
EPS Pre
Earnings per share before the IPO.
P/E Pre
IPO Offer Price ÷ EPS Pre.
EPS Post
Expected earnings per share after the IPO..
P/E (Post Issue)
IPO Offer Price ÷ EPS Post.
Accretion Pharmaceuticals Limited KPI Information
| Particular | KPI as of Mon, Mar 31, 2025. |
|---|---|
| ROE % | 25.2 |
| ROCE % | 11.73 |
| Debt / Equity | 2.52 |
| RoNW % | 72.47 |
| Pat Margin % | 11.51 |
Peers Comparison
No Peer Comparision Available
About Accretion Pharmaceuticals Limited
Accretion Pharmaceuticals Limited, originally established as M/s Accretion Pharmaceuticals, was founded in 2012 by Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra, and Mr. Hardik Mukundbhai Prajapati with the goal of manufacturing healthcare products meeting international standards at competitive prices. The company began as a partnership firm and commenced manufacturing operations in 2014 at its facility located in Ahmedabad, Gujarat.
On October 16, 2023, the firm transitioned into a limited company under the Companies Act, 2013, and was officially incorporated as Accretion Pharmaceuticals Limited on November 29, 2023 (CIN: U21004GJ2023PLC146545).
The company is engaged in the manufacturing and marketing of a wide range of pharmaceutical products including tablets, capsules, oral liquids, external preparations (such as ointments, creams, gels, lotions, shampoos, mouthwashes, and dusting powders), and oral powders (like sachets and dry syrups). Operations include direct sales, contract manufacturing, and loan licensing for various marketers.
Accretion Pharmaceuticals operates in three business verticals:
- Domestic market sales
- Direct export sales
- Sales to merchant exporters under loan license
A significant portion of its products is exported, directly or indirectly, to markets such as Africa, South-East Asia, and Latin America. The company is ISO 9001:2015, ISO 14001:2015, and ISO 22000:2018 certified and is managed by a professional and experienced team.
Accretion Pharmaceuticals IPO Promoters
- Mr. Mayur Popatlal Sojitra
- Mr. Harshad Nanubhai Rathod
- Mr. Vivek Ashok Kumar Patel
- Mr. Hardik Mukundbhai Prajapati
Promoters Holding
Holding Pre Issue
100.00%
Holding Post Issue
73.48%
Accretion Pharmaceuticals IPO Objective
The objects of the present issue of Equity Shares are:
a. Capital expenditure towards purchase of new equipment/machineries, etc.
b. Capital expenditure towards upgradation of existing manufacturing facility;
c. Repayment/prepayment of certain borrowings availed by our Company;
d. Funding working capital requirements; and
e. General Corporate Purpose
Accretion Pharmaceuticals Limited Address / Contact Details
Accretion Pharmaceuticals Limited
29 Xcelon Ind Park 1,
B/h, Intas Pharmaceuticals,
Vasna Chacharvadi, Ahmedabad,
Sanand, Gujarat,-382213
Phone: +91-97148 82929
Email: compliance@accretionpharma.com
Website: https://accretionpharma.com/
IPO Snapshot
Accretion Pharmaceuticals IPO Lot Size
The Accretion Pharmaceuticals IPO has a lot size of 1,200 shares. Retail investors require a minimum investment of ₹1,21,200 by applying for 1 lot (1,200 shares). The maximum application allowed for the retail category is 1 lots (1,200 shares), requiring an investment of ₹1,21,200.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 1,200 | 121,200.00 |
| Retail (Max) | 1 | 1,200 | 121,200.00 |
| S-HNI (Min) | 2 | 2,400 | 242,400.00 |
Issue Reservation
- QIB — 5.48%
- NII — 47.26%
- RII — 47.26%
Book Running Lead Managers
- Jawa Capital Services Private Limited
IPO Documents & Links
Explore More IPOs
Currently Open
Coming Up Next
Disclaimer: This data is for informational purposes only and does not constitute investment advice.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Accretion Pharmaceuticals IPO?
Accretion Pharmaceuticals IPO is a Book-building IPO with a total issue size of ₹29.75 crore. The Accretion Pharmaceuticals IPO price band is ₹96 to 101 per share. The Accretion Pharmaceuticals IPO subscription opens on Wed, May 14, 2025, and closes on Fri, May 16, 2025. The Accretion Pharmaceuticals IPO will be listed on the NSE. KFin Technologies Limited is the registrar for the Accretion Pharmaceuticals IPO.
When will the Accretion Pharmaceuticals IPO open for subscription?
The Accretion Pharmaceuticals IPO opens on Wed, May 14, 2025 and closes on Fri, May 16, 2025
What is Accretion Pharmaceuticals IPO Price Band?
Accretion Pharmaceuticals IPO Price Band is ₹96 to 101 per share.
What is Accretion Pharmaceuticals IPO Lot Size?
Accretion Pharmaceuticals IPO lot size is 1200 shares, Retail investors need a minimum investment of ₹242400 based on the upper price band
What is the minimum investment for Accretion Pharmaceuticals IPO?
The minimum investment for Accretion Pharmaceuticals IPO is ₹242400, based on one lot of 1200 shares at the upper price band of ₹101 per share.
How to apply for Accretion Pharmaceuticals IPO?
Investors can apply for the Accretion Pharmaceuticals IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Fri, May 16, 2025. The application amount remains blocked until the Accretion Pharmaceuticals IPO allotment is finalized.
What is Accretion Pharmaceuticals IPO Issue Size?
Accretion Pharmaceuticals IPO issue size is ₹29.75 crores.
What is the Accretion Pharmaceuticals IPO Allotment Date?
Accretion Pharmaceuticals IPO allotment date is Mon, May 19, 2025.
Who is the Accretion Pharmaceuticals IPO Registrar?
The registrar for Accretion Pharmaceuticals IPO is KFin Technologies Limited. Investors can go to KFin Technologies Limited website to check Accretion Pharmaceuticals IPO allotment status, refund processing, and other IPO-related information.
What is the Accretion Pharmaceuticals IPO GMP?
The Accretion Pharmaceuticals IPO GMP (Grey Market Premium) is ₹5 as of Fri, May 16, 2025. Based on the upper price band of ₹101 per share, the estimated Accretion Pharmaceuticals IPO listing price is ₹106, indicating a potential listing gain of approximately 4.95% over the issue price.
Who is the Accretion Pharmaceuticals IPO Lead Manager?
The book-running lead managers (BRLMs) for the Accretion Pharmaceuticals IPO are Jawa Capital Services Private Limited. The lead managers are responsible for managing the IPO process, including issue structuring, regulatory compliance, marketing the public issue, coordinating with investors, and ensuring a smooth listing process. For complete details, investors should refer to the Accretion Pharmaceuticals IPO Red Herring Prospectus (RHP).